Brief: Alpine Immune Sciences To Collaborate With Merck On Immuno-Oncology Study To Evaluate Alpn-202 In Combination With Keytruda (Pembrolizumab)
30/06/2021 13:23
June 30 (Reuters) - Alpine Immune Sciences Inc ALPN.O :
* ALPINE IMMUNE SCIENCES TO COLLABORATE WITH MERCK ON
IMMUNO-ONCOLOGY STUDY TO EVALUATE ALPN-202 IN COMBINATION WITH
KEYTRUDA® (PEMBROLIZUMAB)
* ALPINE IMMUNE SCIENCES - COLLABORATION WILL EVALUATE
SAFETY AND
EFFICACY OF ALPINE'S ALPN-202 IN COMBINATION WITH MERCK'S
ANTI-PD-1 THERAPY KEYTRUDA
Source text for Eikon: ID:nBw5vtkdNa
Further company coverage: ALPN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpine Immune Sciences
See all newsAlpine Immune Sciences Inc reports results for the quarter ended in January - Earnings Summary
Brief: Alpine Immune Sciences Q1 EPS USD -0.28 Vs. IBES Estimate USD -0.41
Moves: Lazard hires veteran healthcare dealmaker Colocci as vice chairman
U.S. RESEARCH ROUNDUP-Cheesecake Factory, Netflix, Texas Roadhouse
US STOCKS-S&P 500, Nasdaq end sharply higher on soft inflation data, eyes on earnings